Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
  1. Home
  2. Publications
  3. Supplementary Table S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

Supplementary Table S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

Authors:
  • SGShom Goel
    Shom Goel
  • BJBojana Jovanović
    Bojana Jovanović
  • XCXiangying Chu
    Xiangying Chu
  • MHMelissa Hughes
    Melissa Hughes
  • TETimothy K. Erick
    Timothy K. Erick
  • DRDouglas Russo
    Douglas Russo
  • MDMolly DiLullo
    Molly DiLullo
  • EWEileen Wrabel
    Eileen Wrabel
  • RJRinath Jeselsohn
    Rinath Jeselsohn
  • NLNancy U. Lin
    Nancy U. Lin
  • NTNabihah Tayob
    Nabihah Tayob
  • EMElizabeth Mittendorf
    Elizabeth Mittendorf

Open Access
Publisher website
Google Scholar
  • 13 May 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.29053129
Abstract
Representativeness of Study Participants
Keywords
  • BREAST CANCER
  • CLINICAL TRIAL RESULTS
  • PHASE II CLINICAL TRIALS
  • CLINICAL-STAGE RESEARCH
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.